Wright Investors Service Comprehensive Report for Exelixis, Inc.
27 Feb 2014
Available for Immediate Download
Quantitative analyses of financial statements (Income Statement, Balance Sheet and Sources of Capital), extensive ratio tables (Accounting, Asset Utilization, Employee Efficiency, Fixed Charges Coverage, Leverage Analysis, Liquidity Analysis, Per-share Data and Profitability Analysis) and proprietary Wright Quality Rating analyses tables. The Wright Quality Rating, a measure of corporate risk, examines the liquidity of the stock, financial strength, profitability and corporate growth characteristics of Exelixis, Inc. There is a textual review of the financial results of Exelixis, Inc. versus Merrimack Pharmaceuticals Inc, Enzon Pharmaceuticals, Inc. and Halozyme Therapeutics, Inc. The comparative analysis of these companies compares Sales (sales, sales growth and sales per employee), Company Valuations (Price/Earnings, Price/Book, Price/Sales and 52-Week Price Change) and Financial Position (Long-term Debt/Equity). Also included for Exelixis, Inc. are the Company Description, Recent Stock Performance, Profitability Analysis, Dividend Analysis, and Key Data Items (Ticker, Major Industry, Sub-Industry, Fiscal Year End Month, Employees, Share Type, Market Capitalization, Total Shares Outstanding and Number of Closely Held Shares.) Additional research for Exelixis, Inc. includes tables with up to 10-years of history of computed ratios, sales, earnings, and security prices.